Peer-influenced content. Sources you trust. No registration required. This is HCN.

ASCO Educational BookIntroducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations

Despite the array of intensive treatment approaches, local control and overall survival rates in patients with advanced-stage disease remain low (approximately 40%–50% at 5 years). This review discusses recent studies integrating ICIs into definitive treatment regimens.